The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
German companies including Merck and ZEISS expressed strong confidence and high hopes for the Chinese market at the China ...
Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...
Yesterday, US health officials proposed getting rid of oral drugs containing the decongestant phenylephrine over concerns ...
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
AstraZeneca’s presence in South Africa has become a driving force in global health research, contributing significantly to respiratory, cardiovascular, and oncology therapeutic areas. The ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback